BaCKgRoUND aND aIMS:Hepatitis C virus (HCV) and alcohol use are patient risk factors for accelerated fibrosis progression, yet few randomized controlled trials have tested clinic-based alcohol interventions. appRoaCH aND ReSUltS: A total of 181 patients with HCV and qualifying alcohol screener scores at three liver center settings were randomly assigned to the following: (1) medical provider-delivered Screening, Brief Intervention, and Referral to Treatment (SBIRT), including motivational interviewing counseling and referral out for alcohol treatment (SBIRT-only), or (2) SBIRT plus 6 months of integrated colocated alcohol therapy (SBIRT + Alcohol Treatment). The timeline followback method was used to assess alcohol use at baseline and 3, 6, and 12 months. Coprimary outcomes were alcohol abstinence at 6 months and heavy drinking days between 6 and 12 months. Secondary outcomes included grams of alcohol consumed per week at 6 months. Mean therapy hours across 6 months were 8.8 for SBIRT-only and 10.1 for SBIRT + Alcohol Treatment participants. The proportion of participants exhibiting full alcohol abstinence increased from baseline to 3, 6, and 12 months in both treatment arms, but no significant differences were found between arms (baseline to 6 months, 7.1% to 20.5% for SBIRT-only; 4.2% to 23.3% for SBIRT + Alcohol Treatment; P = 0.70). Proportions of participants with any heavy drinking days decreased in both groups at 6 months but did not significantly differ between the SBIRT-only (87.5% to 26.7%) and SBIRT + Alcohol Treatment (85.7% to 42.1%) arms (P = 0.30). Although both arms reduced average grams of alcohol consumed per week from baseline to 6 and 12 months, between-treatment effects were not significant.
CoNClUSIoNS:Patients with current or prior HCV infection will engage in alcohol treatment when encouraged by liver medical providers. Liver clinics should consider implementing provider-delivered SBIRT and tailored alcohol treatment referrals as part of the standard of care. (Hepatology A ffecting an estimated 71 million people worldwide, (1) chronic hepatitis C virus (HCV) infection can lead to fibrosis, cirrhosis, and life-shortening complications of portal hypertension and hepatocellular carcinoma. (2) Alcohol use in the setting of HCV infection is associated with increased rates of fibrosis progression, liver-related mortality, and overall mortality. (3) Compared with people without HCV, people with HCV infection living in the United States are estimated to be excessive drinkers 1.3 times more often. (4) Consequently, guidelines recommend abstinence from alcohol and clinical interventions to facilitate alcohol cessation in patients with active infection. (5,6) Even after HCV cure with therapy, patients with cirrhosis remain at higher risk for fibrosis progression and hepatocellular carcinoma; these patients are particularly cautioned against excessive alcohol use. (5,6) Screening, Brief Intervention, and Referral to Treatment (SBIRT) is an evidence-based alcohol reduction practice. This 5-to 10-minute...